Senseonics Gets FDA Approval for Eversense Implantable CGM System

Senseonics CGM system received FDA approval.

Image: Eversense

Senseonics, a company that develops implantable continuous glucose monitoring (CGM) system for people with diabetes, received FDA approval for the non-adjunctive indication (dosing claim) for its Eversense CGM.

Related Nemaura’s SugarBeat Non-Invasive CGM Gets CE Approval

The CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. People with diabetes can use this system instead of the traditional finger prick tests to make diabetes-related decisions.

“We are pleased with the results of the European Eversense PMCF registry which demonstrate the safety of the Eversense CGM System in a large group of patients,” said Katherine Tweden, PhD, Vice President of Clinical Sciences at Senseonics. “This post-market study was an opportunity to evaluate the real-world experience of Eversense and Eversense XL CGM as patients wore their first, second, third and fourth sensors. The results, with 3,667 patient-years of wear, demonstrated a strong safety profile over repeat sensor cycles for the first long-term implantable sensor.”

Related Medtronic Buys AI-powered Nutrition Platform Nutrino to Boost Diabetes Offering

Past clinical studies evaluated the safety of the system using a study design of one insertion and removal cycle. Safety data from 3,066 Eversense users from 15 European countries was collected and reported. Repeat insertions of the Eversense CGM confirmed the safety profile of prior studies and showed it to be safe for long-term continuous use.

WT | Wearable Technologies Conference in San Francisco on July 9-10

The most innovative wearables event will be back on July 9-10 in beautiful San Francisco at SEMICON West to celebrate the 34th edition of the WT | Wearable Technologies Conference Series. Topics include data analytics in professional sports, prevention, treatment and rehabilitation with wearables, the future of digital health, medication and adherence, smart patches, workflow optimization and workforce safety and much more – featuring international leaders and experts of the wearables industry´s biggest names including Abbott, Autodesk, Datwyler, Kopin, Maxim Integrated, Multek, NFLPA, Omron, SharkDreams, Qualcomm, and many more. Register now to be part of #WTUS19

Sam Draper
June 13, 2019

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Qualcomm Adds aptX Lossless, New Bluetooth Lossless Audio Technology To Its Audio Portfolio

Qualcomm has introduced aptX Lossless audio technology to its already extensive audio portfolio ...

Oura, WHOOP, BioStrap and BioIntelliSense Invading Health Monitoring Space With Biometric Wearables

Biometric wearables like Whoop bracelets, Oura rings, BioStrap and BioStickers, are all showing...

Oscar Closes $140M New Funding Round, Led By Tiger Global Management

Oscar Health, a New York City-based health insurance technology company, has raised $140 million...

Gartner For the First Time Lists Resco in its Magic Quadrant for Mobile App Development Platforms

Resco in MADP provides mobile solutions for Microsoft Dynamics 365/CRM and Salesforce.
Discover more